Michael Schmidt

“I noticed there was really no difference in response rate in the second or third line patients during the mid-80s for both cohorts or both subsets. is there something going on there or do you think that's just coincidence given the small sample size um and then i had a question on the phase three study anything else…”

“So, in these GI cancer expansion cohorts, could you just comment a bit about how you're approaching dose selection here, and to what degree you can implement learnings from the colorectal cancer experience.”

“I had one on the BTK, the greater program, sticking with hematology. Maybe comment a bit about how you're tracking towards completing the first registration study in relapse of RAD3 CLL.”

“Oh, hey, thanks for taking my question, and congrats on all the progress and news today. I had a question on Dirax and RASAB, and I'm just curious if you have any early feedback from the EAP program and how the products perhaps are performing relative to the clinical trial experience.”